Cerebrospinal Fluid Chloride Is Associated with Disease Activity of Relapsing–Remitting Multiple Sclerosis: A Retrospective Cohort Study
暂无分享,去创建一个
A. Kermode | Yaxin Lu | Zifeng Liu | L. Ling | W. Qiu | Chunxin Liu | Xin-Yue Fang | Yongmei Fu | Yaxin Lu
[1] M. Süße,et al. Kappa Free Light Chains in Cerebrospinal Fluid in Inflammatory and Non-Inflammatory Neurological Diseases , 2022, Brain sciences.
[2] Zhuoyi Liu,et al. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. , 2021, Autoimmunity reviews.
[3] J. Nicholas,et al. Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis , 2020, Advances in Therapy.
[4] E. Leray,et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.
[5] S. Hauser,et al. Treatment of Multiple Sclerosis: A Review. , 2020, The American journal of medicine.
[6] K. Rejdak,et al. Biomarkers in Multiple Sclerosis: a review of diagnostic and prognostic factors. , 2020, Neurologia i neurochirurgia polska.
[7] B. Zeydan,et al. Impact of Age on Multiple Sclerosis Disease Activity and Progression , 2020, Current Neurology and Neuroscience Reports.
[8] A. Chan,et al. Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study , 2020, Therapeutic Advances in Neurological Disorders.
[9] F. Benninger,et al. Does CSF pleocytosis have a predictive value for disease course in MS? , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[10] V. Tomassini,et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis , 2019, JAMA neurology.
[11] Xavier Montalban,et al. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis , 2019, Nature Reviews Neurology.
[12] Robert C Reiner,et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.
[13] M. Comabella,et al. Biomarkers in Multiple Sclerosis. , 2019, Cold Spring Harbor perspectives in medicine.
[14] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[15] G. Pardo,et al. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations , 2017, Journal of Neurology.
[16] Marc Debouverie,et al. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study , 2017, Neuroepidemiology.
[17] K. Staley,et al. Chloride Dysregulation, Seizures, and Cerebral Edema: A Relationship with Therapeutic Potential , 2017, Trends in Neurosciences.
[18] L. Vinay,et al. Chloride Regulation: A Dynamic Equilibrium Crucial for Synaptic Inhibition , 2016, Neuron.
[19] D. Centonze,et al. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression , 2016, Journal of Neuroinflammation.
[20] Jianwen Cai,et al. Modelling recurrent events: a tutorial for analysis in epidemiology. , 2015, International journal of epidemiology.
[21] B. Casanova,et al. Perturbed Glucose Metabolism: Insights into Multiple Sclerosis Pathogenesis , 2014, Front. Neurol..
[22] Gabriele Deidda,et al. Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives , 2014, Front. Cell. Neurosci..
[23] W. Boron,et al. Intracellular pH regulation by acid-base transporters in mammalian neurons , 2014, Front. Physiol..
[24] Xusheng Huang,et al. Significance of chloride contents in cerebrospinal fluid and plasma and their ratio in early diagnosis and differential diagnosis of central nervous system infections , 2014 .
[25] J. Lechner-Scott,et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. , 2013, Brain : a journal of neurology.
[26] M. Kamermans,et al. Brain white matter oedema due to ClC-2 chloride channel deficiency: an observational analytical study , 2013, The Lancet Neurology.
[27] G. Pawelec. Hallmarks of human “immunosenescence”: adaptation or dysregulation? , 2012, Immunity & Ageing.
[28] S. Skaper. Ion channels on microglia: therapeutic targets for neuroprotection. , 2011, CNS & neurological disorders drug targets.
[29] T. Freund,et al. Relationship between neuronal vulnerability and potassium-chloride cotransporter 2 immunoreactivity in hippocampus following transient forebrain ischemia , 2008, Neuroscience.
[30] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.
[31] A. Rovira,et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.
[32] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[33] F. Galeffi,et al. Changes in Intracellular Chloride after Oxygen–Glucose Deprivation of the Adult Hippocampal Slice: Effect of Diazepam , 2004, The Journal of Neuroscience.
[34] Dean A Seehusen,et al. Cerebrospinal fluid analysis. , 2003, American family physician.
[35] Ryozo Ohno,et al. [Cerebrospinal fluid in multiple sclerosis]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.
[36] B E Kendall,et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.
[37] E. Schoen. Spinal fluid chloride: a test 40 years past its time. , 1984, JAMA.
[38] R. Prentice,et al. Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .
[39] T. Alsaadi,et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. , 2019, Multiple sclerosis and related disorders.
[40] G. Feng,et al. The Chloride Transporter Na+-K+-Cl− Cotransporter Isoform-1 Contributes to Intracellular Chloride Increases after In Vitro Ischemia , 2006, The Journal of Neuroscience.
[41] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.